- DURECT (NASDAQ:DRRX) is up 7% premarket on average volume following its announcement that it has submitted its responses to the CRL it received from the FDA in February 2014 pertaining to its marketing application for pain med POSIMIR (bupivacaine) citing the need for more safety data.
- The agency's action date in December 27.
Durect files response to Posimir CRL; shares up 7% premarket
Recommended For You
More Trending News
About DRRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
DRRX | - | - |
DURECT Corporation |